Amarin Corp Plcuk (AMRN) Current Deferred Revenue (2013 - 2024)
Amarin Corp Plcuk (AMRN) reported Current Deferred Revenue of $4.4 million for Q1 2024, down 70.14% year-over-year from $14.9 million in Q2 2023, and down 8.27% quarter-over-quarter from $4.8 million in Q4 2023.
Amarin Corp Plcuk (AMRN) Current Deferred Revenue (2013 - 2024) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 11 years of Current Deferred Revenue data on file, last reported at $4.4 million in Q1 2024.
- Current Deferred Revenue for Q1 2024 came in at $4.4 million, down 70.14% year-over-year; the trailing twelve-month figure through Mar 2024 was $4.4 million (down 70.14% YoY), and the FY2023 annual result was $4.8 million, down 68.4% from the prior year.
- Current Deferred Revenue declined to $4.4 million in Q1 2024 per AMRN's latest filing, from $4.8 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $21.8 million in Q1 2020 and troughed at $4.4 million in Q1 2024.
- A 5-year average of $14.5 million and a median of $16.3 million in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2020 and 2024: Current Deferred Revenue rose 8.15% in 2020, then slumped 70.14% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $18.6 million in 2020, then slipped by 10.32% to $16.7 million in 2021, then retreated by 8.16% to $15.3 million in 2022, then tumbled by 68.4% to $4.8 million in 2023, then slipped by 8.27% to $4.4 million in 2024.
- Business Quant data shows AMRN's Current Deferred Revenue at $4.4 million in Q1 2024, $4.8 million in Q4 2023, and $5.0 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 4.45 Mn |
| Dec 31, 2023 | 4.85 Mn |
| Sep 30, 2023 | 4.97 Mn |
| Jun 30, 2023 | 5.36 Mn |
| Mar 31, 2023 | 14.90 Mn |
| Dec 31, 2022 | 15.35 Mn |
| Sep 30, 2022 | 15.70 Mn |
| Jun 30, 2022 | 16.01 Mn |
| Mar 31, 2022 | 16.34 Mn |
| Dec 31, 2021 | 16.71 Mn |
| Sep 30, 2021 | 17.13 Mn |
| Jun 30, 2021 | 17.97 Mn |
| Mar 31, 2021 | 17.97 Mn |
| Dec 31, 2020 | 18.63 Mn |
| Sep 30, 2020 | 18.91 Mn |
| Jun 30, 2020 | 20.21 Mn |
| Mar 31, 2020 | 21.81 Mn |
| Dec 31, 2019 | 20.85 Mn |
| Sep 30, 2019 | 19.58 Mn |
| Jun 30, 2019 | 19.74 Mn |